How Medicare’s New Drug Price Negotiation Program Could Expand Access to Selected Drugs September 26, 2023 Issue Brief This brief examines how Part D enrollees’ access to and utilization of the first set of 10 selected drugs could be affected by the new Part D coverage and formulary requirements for selected drugs established by the Inflation Reduction Act and in CMS guidance, as well as the potential for lower out-of-pocket costs.
What are the recent and forecasted trends in prescription drug spending? September 15, 2023 Slideshow
KFF Examines Challenges in Navigating Coverage for Opill, the First Over-the-Counter Daily Oral Contraceptive Pill, Coming to Market Next Year September 14, 2023 News Release As Opill—the first over-the-counter daily oral contraceptive pill in the United States—is expected to be available for purchase in early 2024, new research conducted by KFF examines barriers to its accessibility for consumers and challenges in providing insurance coverage for it. Based on interviews with nearly 80 representatives from private…
Over-the-Counter Oral Contraceptive Pills September 14, 2023 Issue Brief Oral contraceptives are the most commonly used method of reversible contraception in the U.S. In July 2023, the FDA approved Opill, the first daily oral contraceptive pill to become available over the counter (OTC) without a doctor’s prescription. This issue brief provides an overview of OTC oral contraceptives and laws and policies related to insurance coverage.
The Health Wonk Shop: Probing the Legal Arguments in the Drug Industry’s Challenges to Medicare Drug Price Negotiations September 12, 2023 Event With the Biden administration’s announcement of the first 10 drugs to be negotiated for Medicare as part of the Inflation Reduction Act (IRA), an array of legal challenges from the pharmaceutical industry is potentially the biggest obstacle to implementation. In court filings, individual drugmakers and the industry’s main lobbying group…
Medicaid Utilization and Spending on New Drugs Used for Weight Loss September 8, 2023 Blog This brief discusses Medicaid coverage of weight-loss drugs, recent trends in Medicaid utilization and gross spending on new drugs used for weight loss, and the potential implications of those new drugs for Medicaid programs and enrollees.
The 4 Arguments You Will Hear Against Drug Price Negotiation September 6, 2023 Perspective As the Biden administration begins the process of negotiation drug prices for Medicare as authorized in the Inflation Reduction Act, KFF’s Larry Levitt probes some of the arguments against it and the policy and political implications of the debate in this New York Times op-ed column.
Will Where You Live Determine Access and Coverage of Emerging Anti-Obesity Drugs? August 30, 2023 Blog The U.S. Midwest and South regions have higher average obesity rates among adults. What does this mean for access and coverage of prescription drugs for weight loss?
Public Opinion on Prescription Drugs and Their Prices August 21, 2023 Poll Finding This chart collection draws on recent KFF poll findings to provide an in-depth look at the public’s attitudes toward prescription drugs and their prices. Results include Americans’ opinions on drug affordability, pharmaceutical companies, and various potential measures that could lower prices.
Drugs Used for Weight Loss Could Cost Americans Much More Than People in Peer Countries August 17, 2023 News Release In addition to having the highest obesity rates, the U.S is currently facing significantly higher prices for several major drugs used for weight loss and other health needs, according to a new KFF analysis of the list prices for semaglutide and tirzepatide drugs. Ozempic, which has been approved in the…